Please cancel Claims 1-12. Please add new claims 39-40. Please amend Claims 13, 24 and 37-38 as follows:

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)

7. (Canceled)

8. (Canceled)

9. (Canceled)

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (Currently amended) A method for making a ~~non-liposomal~~ pharmaceutical formulation comprising:

combining a pharmaceutically active agent with a phospholipid to produce a proliposomal combination;

coating said combination with an enteric coating material to produce a coated product, wherein said enteric coating is in contact with at least a portion of said proliposomal combination; and

forming said coated product into a capsule~~, liquid~~ or suspension.

14. (Original) The method of Claim 13, wherein said pharmaceutically active agent is a poorly water soluble drug.

15. (Original) The method of Claim 13, wherein said pharmaceutically active agent is selected from the group consisting of griseofulvin, famotidine, meclizine, cyclosporine, carbamazipine, methotrexate, itraconazole, dipyridamole, mercaptopurine, halofantrine, amiodarone, lomustine, testosterone, misoprostil, etoposide, rifamycin, azathioprine, glyburide, tolbutamide, aminoglutethimide, taxol, clofibrate, nifedipine, methyldopa, ramipril and dicumarol.

16. (Original) The method of Claim 13, wherein said phospholipid is a phosphatidyl phospholipid.

17. (Original) The method of Claim 13, wherein said phospholipid is selected from the group consisting of distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, egg PC, soy PC, DMPG, DMPA, DPPG, DPPA, DSPG, DSPA, phosphatidylserine and sphigomyelin.

18. (Original) The method of Claim 13, wherein said enteric coating material is selected from the group consisting of cellulose acetate phthalate, alginates, alkali-soluble acrylic resins, hydroxypropyl methylcellulose phthalate, methacrylate-methacrylic acid coplymers, polyvinyl acetate phthalate and styrol maleic acid copolymers.

19. (Original) The method of Claim 13, wherein said coating comprises spraying said combination with said enteric coating material.

B1 cont.

20. (Original) The method of Claim 13, further comprising combining at least one additional ingredient which is pharmaceutically inactive with said pharmaceutically active agent.

21. (Original) The method of Claim 20, wherein said at least one additional ingredient is selected from the group consisting of carriers, diluents and lubricants.

22. (Original) The method of Claim 20, wherein said at least one additional ingredient is selected from the group consisting of microcrystalline cellulose, starch, lactose, talc, mannitol, polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, ethyl cellulose, fatty acids, fatty acid salts, glyceryl behenate, dextrose and dicalcium phosphate.

23. (Original) The method of Claim 13, wherein said pharmaceutically active agent is selected from the group consisting of anorexics, analgesics, antiarthritics, adrenergic blocking agents, steroids, vaccines, peptides, proteins, hormones, antibodies, antibiotics, antiviral agents, vitamins, nucleotides, nutritional agents, enzymes, genes, genetic material, cytotoxins, bacteria, microbes and viral agents.

24. (Currently amended) A method of making a ~~non-liposomal~~ pharmaceutical formulation comprising:

combining at least one pharmaceutically active agent with at least one phospholipid in a non-aqueous solvent to produce a proliposomal combination;

evaporating said non-aqueous solvent; and

applying an enteric coating material to said pharmaceutically active agent and said phospholipid, wherein said enteric coating is in contact with at least a portion of said proliposomal combination.

25. (Original) The method of Claim 24, wherein said pharmaceutically active agent is a poorly water soluble drug.

26. (Original) The method of Claim 24, wherein said pharmaceutically active agent is selected from the group consisting of griseofulvin, famotidine, meclizine, cyclosporine, carbamazipine, methotrexate, itraconazole, dipyridamole, mercaptopurine, halofantrine, amiodarone, lomustine, testosterone, misoprostil, etoposide, rifamycin, azathioprine, glyburide, tolbutamide, aminoglutethimide, taxol, clofibrate, nifedipine, methyldopa, ramipril and dicumarol.

27. (Original) The method of Claim 24, wherein said phospholipid is a phosphatidyl phospholipid.

28. (Original) The method of Claim 24, wherein said phospholipid is selected from the group consisting of distearoyl phosphatidylcholine, dipalmitoyl phosphatidylcholine, dimyristoyl phosphatidylcholine, egg PC, soy PC, DMPG, DMPA, DPPG, DPPA, DSPG, DSPA, phosphatidylserine and sphigomyelin.

29. (Original) The method of Claim 24, wherein said enteric coating material is selected from the group consisting of cellulose acetate phthalate, alginates, alkali-soluble acrylic resins, hydroxypropyl methylcellulose phthalate, methacrylate-methacrylic acid coplymers, polyvinyl acetate phthalate and styrol maleic acid copolymers.

30. (Original) The method of Claim 24, wherein said applying an enteric coating material comprises spraying said pharmaceutically active agent and said phospholipid with said enteric coating material.

31. (Original) The method of Claim 24, further comprising combining at least one additional ingredient which is pharmaceutically inactive with said pharmaceutically active agent.

32. (Original) The method of Claim 31, wherein said at least one additional ingredient is selected from the group consisting of carriers, diluents and lubricants.

33. (Original) The method of Claim 31, wherein said at least one additional ingredient is selected from the group consisting of microcrystalline cellulose, starch, lactose, talc, mannitol, polyethylene glycol, polyvinylpyrrolidone, hydroxypropylmethyl cellulose, ethyl cellulose, fatty acids, fatty acid salts, glyceryl behenate, dextrose and dicalcium phosphate.

34. (Original) The method of Claim 24, wherein said pharmaceutically active agent is selected from the group consisting of anorexics, analgesics, antiarthritics, adrenergic blocking agents, steroids, vaccines, peptides, proteins, hormones, antibodies, antibiotics, antiviral agents, vitamins, nucleotides, nutritional agents, enzymes, genes, genetic material, cytotoxins, bacteria, microbes and viral agents.

35. (Original) The method of Claim 24, wherein said formulation is in a form selected from the group consisting of capsules~~,~~ and suspensions ~~and liquids~~.

36. (Original) The method of Claim 24, wherein said formulation is in tablet form.

37. (Currently amended) A method for delivering the pharmaceutical formulation ~~of Claim 1~~ produced by the method of Claim 13 to a mammal comprising orally administering said pharmaceutical formulation to said mammal.

38. (Currently amended) A method for diagnosing, preventing or treating an illness in a mammal comprising administering the pharmaceutical formulation ~~of Claim 1~~ produced by the method of Claim 13, further comprising providing ~~wherein~~ said pharmaceutical agent ~~is provided~~ in a biologically active dose.

39. (New) The method of Claim 13, wherein said pharmaceutically active agent is a water labile drug.

40. (New) The method of Claim 24, wherein said pharmaceutically active agent is a water labile drug.